Matches in SemOpenAlex for { <https://semopenalex.org/work/W771855616> ?p ?o ?g. }
Showing items 1 to 42 of
42
with 100 items per page.
- W771855616 abstract "OBJECTIVE: to evaluate the efficacy and safety profile of dimethylfumarate in MS patients treated in our unit.BACKGROUND: The arrival of oral treatments in MS modified the future of first line MS treatment. Dimethylfumarate has been evaluated in DEFINE and CONFIRM studies and shows good outcomes in term of efficacy and safety in RRMS patients.METHODS: we prospectively collected data of the patients who received dimethylfumarate from the first day of availability in our unit. Age, sex, disease duration, prior treatment, EDSS baseline, MRI data at baseline were registered. The clinical and biological adverse events, and the evolution of the disease have been assessed during the regular follow-up visits, wich are still ongoing.RESULTS: since the March 5 of 2014, 114 MS patients received dimethylfumarate, with a median age of 37 years (range 19-67), and a ratio female/male of 2/1. The median disease duration was 5,9 years (range 0,3-35) and 72[percnt] had already received a MS disease-modifying therapy. For 17[percnt] of them, it was a second line MS therapy. 61[percnt] of patients had at least one relapse and 46[percnt] radiological activity the past year. Median EDSS at baseline was 2 (range 0-6,5).During the follow up, 18[percnt] of patients showed no side effect. Abdominal pain (19[percnt]) was the most common adverse event, followed by hot flash (13[percnt]), flush (8[percnt]), pruritus (5[percnt]) and diarrhea (3,5[percnt]). Five patients had to stop treatment due to intolerance. We noticed six asymptomatic cases of hyper-eosinophilia who occurred during the first month and were normalized at 3 month.94[percnt] of patients remained stable without relapse. Six patients presented relapse, whose five during the first 3-month of treatment.CONCLUSION: We show in our study that Dimethylfumarate has a good profile of tolerance, despite still frequent minor adverse effects. One-year efficacy data will be presented. Disclosure: Dr. Aboab has nothing to disclose. Dr. Deschamps has nothing to disclose. Dr. Gueguen has received personal compensation for activities with Novartis. Dr. Obadia has nothing to disclose. Dr. Moulignier has nothing to disclose. Dr. Gout has received personal compensation for activities with Allergan, Inc., Almirall, Bayer-Schering, Biogen Idec, Genzyme, Novartis, Merck Serono, Sanofi, and Teva." @default.
- W771855616 created "2016-06-24" @default.
- W771855616 creator A5000767968 @default.
- W771855616 creator A5006513938 @default.
- W771855616 creator A5039237964 @default.
- W771855616 creator A5046045433 @default.
- W771855616 creator A5082934897 @default.
- W771855616 creator A5088638640 @default.
- W771855616 date "2015-04-06" @default.
- W771855616 modified "2023-09-24" @default.
- W771855616 title "Observational prospective study in Multiple Sclerosis patients treated with Dimethylfumarate. (P3.271)" @default.
- W771855616 hasPublicationYear "2015" @default.
- W771855616 type Work @default.
- W771855616 sameAs 771855616 @default.
- W771855616 citedByCount "0" @default.
- W771855616 crossrefType "journal-article" @default.
- W771855616 hasAuthorship W771855616A5000767968 @default.
- W771855616 hasAuthorship W771855616A5006513938 @default.
- W771855616 hasAuthorship W771855616A5039237964 @default.
- W771855616 hasAuthorship W771855616A5046045433 @default.
- W771855616 hasAuthorship W771855616A5082934897 @default.
- W771855616 hasAuthorship W771855616A5088638640 @default.
- W771855616 hasConcept C118552586 @default.
- W771855616 hasConcept C126322002 @default.
- W771855616 hasConcept C197934379 @default.
- W771855616 hasConcept C23131810 @default.
- W771855616 hasConcept C2780640218 @default.
- W771855616 hasConcept C71924100 @default.
- W771855616 hasConceptScore W771855616C118552586 @default.
- W771855616 hasConceptScore W771855616C126322002 @default.
- W771855616 hasConceptScore W771855616C197934379 @default.
- W771855616 hasConceptScore W771855616C23131810 @default.
- W771855616 hasConceptScore W771855616C2780640218 @default.
- W771855616 hasConceptScore W771855616C71924100 @default.
- W771855616 hasLocation W7718556161 @default.
- W771855616 hasOpenAccess W771855616 @default.
- W771855616 hasPrimaryLocation W7718556161 @default.
- W771855616 hasVolume "84" @default.
- W771855616 isParatext "false" @default.
- W771855616 isRetracted "false" @default.
- W771855616 magId "771855616" @default.
- W771855616 workType "article" @default.